Upper class drug companies targeting at 100 Billion Won of sales.

Published: 2003-04-15 07:00:00

Updated: 2003-04-15 07:00:00

100 billion won of the sales is the most attractive target for most of ambitious drug companies to put their ultimate goals this year. It also implies a symbolic number for the upper class drug companies to pursue, including Dongshin, Yungjin, Samjin, Bukwang, Lilly Korea and BMS Korea.

Samjin...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK